There were 18 serious adverse events reported in the rituximab groups ( four in the rituximab induction group and 14 in the maintenance rituximab group ) , 12 of which were grade 3 or 4 ( five infections , three allergic reactions , and four cases of neutropenia ) , all of which fully resolved .